- Home
- Publications
- Publication Search
- Publication Details
Title
PD-1/PD-L1 immune checkpoint: Potential target for cancer therapy
Authors
Keywords
-
Journal
JOURNAL OF CELLULAR PHYSIOLOGY
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2018-09-07
DOI
10.1002/jcp.27172
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- PD-L1 promotes OCT4 and Nanog expression in breast cancer stem cells by sustaining PI3K/AKT pathway activation
- (2017) Sheema Almozyan et al. INTERNATIONAL JOURNAL OF CANCER
- Rise of PD-L1 expression during metastasis of colorectal cancer: Implications for immunotherapy
- (2017) Huan Bin Wang et al. Journal of Digestive Diseases
- New treatment options for metastatic renal cell carcinoma with prior anti-angiogenesis therapy
- (2017) Kevin Zarrabi et al. Journal of Hematology & Oncology
- Combined Radiotherapy and Anti–PD-L1 Antibody Synergistically Enhances Antitumor Effect in Non–Small Cell Lung Cancer
- (2017) Xiaomei Gong et al. Journal of Thoracic Oncology
- Tumor Suppressor microRNAs Contribute to the Regulation of PD-L1 Expression in Malignant Pleural Mesothelioma
- (2017) Steven C. Kao et al. Journal of Thoracic Oncology
- The JAK/STAT pathway is involved in the upregulation of PD-L1 expression in pancreatic cancer cell lines
- (2017) Toshifumi Doi et al. ONCOLOGY REPORTS
- PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome
- (2017) Hashem O. Alsaab et al. Frontiers in Pharmacology
- PD-1/PD-L1 Pathway in Breast Cancer
- (2017) Florian Schütz et al. Oncology Research and Treatment
- The immune checkpoint ligand PD-L1 is upregulated in EMT-activated human breast cancer cells by a mechanism involving ZEB-1 and miR-200
- (2017) Muhammad Zaeem Noman et al. OncoImmunology
- Correlation of PDL1 tumor expression and treatment outcomes in patients with renal cell carcinoma (RCC) receiving tyrosine kinase inhibitors: COMPARZ study analysis.
- (2017) Toni K. Choueiri et al. JOURNAL OF CLINICAL ONCOLOGY
- Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab
- (2016) P. F. Ferrucci et al. ANNALS OF ONCOLOGY
- Immune Blockade Inhibition in Breast Cancer
- (2016) IOANNIS A VOUTSADAKIS ANTICANCER RESEARCH
- Non–Small Cell Lung Cancer, PD-L1, and the Pathologist
- (2016) Keith M. Kerr et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- Tumor-Intrinsic PD-L1 Signals Regulate Cell Growth, Pathogenesis, and Autophagy in Ovarian Cancer and Melanoma
- (2016) Curtis A. Clark et al. CANCER RESEARCH
- Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab
- (2016) Benjamin Weide et al. CLINICAL CANCER RESEARCH
- Epithelial-Mesenchymal Transition Is Associated with a Distinct Tumor Microenvironment Including Elevation of Inflammatory Signals and Multiple Immune Checkpoints in Lung Adenocarcinoma
- (2016) Y. Lou et al. CLINICAL CANCER RESEARCH
- Emerging therapeutics in refractory renal cell carcinoma
- (2016) Vadim S. Koshkin et al. EXPERT OPINION ON PHARMACOTHERAPY
- PD-1/PD-L1 blockade in cancer treatment: perspectives and issues
- (2016) Junzo Hamanishi et al. International Journal of Clinical Oncology
- Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
- (2016) Rita Nanda et al. JOURNAL OF CLINICAL ONCOLOGY
- Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy
- (2016) Weijie Ma et al. Journal of Hematology & Oncology
- PD-L1 expression in colorectal cancer is associated with microsatellite instability, BRAF mutation, medullary morphology and cytotoxic tumor-infiltrating lymphocytes
- (2016) Matthew W Rosenbaum et al. MODERN PATHOLOGY
- Significance of Programmed Death Ligand 1 (PD-L1) Immunohistochemical Expression in Colorectal Cancer
- (2016) Lisha Wang et al. Molecular Diagnosis & Therapy
- Acid-Activatable Versatile Micelleplexes for PD-L1 Blockade-Enhanced Cancer Photodynamic Immunotherapy
- (2016) Dangge Wang et al. NANO LETTERS
- miR-424(322) reverses chemoresistance via T-cell immune response activation by blocking the PD-L1 immune checkpoint
- (2016) Shaohua Xu et al. Nature Communications
- The tumor suppressor miR-138-5p targets PD-L1 in colorectal cancer
- (2016) Lian Zhao et al. Oncotarget
- Nivolumab in renal cell carcinoma: latest evidence and clinical potential
- (2016) Camille Mazza et al. Therapeutic Advances in Medical Oncology
- PD-L1 expression in non-small cell lung cancer: Correlations with genetic alterations
- (2016) Andreas H. Scheel et al. OncoImmunology
- Regulation of PD-L1: a novel role of pro-survival signalling in cancer
- (2015) J. Chen et al. ANNALS OF ONCOLOGY
- Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
- (2015) Suzanne L. Topalian et al. CANCER CELL
- Abstract S1-09: A phase Ib study of pembrolizumab (MK-3475) in patients with advanced triple-negative breast cancer
- (2015) Rita Nanda et al. CANCER RESEARCH
- Classifying Cancers Based on T-cell Infiltration and PD-L1
- (2015) Michele W.L. Teng et al. CANCER RESEARCH
- The Role of Anti-PD-1/PD-L1 Agents in Melanoma: Progress to Date
- (2015) Katy K. Tsai et al. DRUGS
- Anti-PD-1 and PD-L1 therapy for bladder cancer: what is on the horizon?
- (2015) Srinath Sundararajan et al. Future Oncology
- Anti–PD-1/PD-L1 therapy of human cancer: past, present, and future
- (2015) Lieping Chen et al. JOURNAL OF CLINICAL INVESTIGATION
- Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial
- (2015) Robert J. Motzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer
- (2015) Scott N. Gettinger et al. JOURNAL OF CLINICAL ONCOLOGY
- VEGF-A modulates expression of inhibitory checkpoints on CD8+T cells in tumors
- (2015) Thibault Voron et al. JOURNAL OF EXPERIMENTAL MEDICINE
- PDL1 Regulation by p53 via miR-34
- (2015) Maria Angelica Cortez et al. JNCI-Journal of the National Cancer Institute
- Programmed Death-Ligand 1 Immunohistochemistry in Lung Cancer: In what state is this art?
- (2015) Keith M. Kerr et al. Journal of Thoracic Oncology
- Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
- (2015) Jeffrey S Weber et al. LANCET ONCOLOGY
- The Clinical Relevance of the miR-197/CKS1B/STAT3-mediated PD-L1 Network in Chemoresistant Non-small-cell Lung Cancer
- (2015) Yu Fujita et al. MOLECULAR THERAPY
- Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
- (2015) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- (2015) Edward B. Garon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
- (2015) Stephen M. Ansell et al. NEW ENGLAND JOURNAL OF MEDICINE
- The prognostic significance of PD-L1 in bladder cancer
- (2015) YIDE HUANG et al. ONCOLOGY REPORTS
- New immunotherapies targeting the PD-1 pathway
- (2015) Jordan M. Chinai et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- The Microsatellite Instable Subset of Colorectal Cancer Is a Particularly Good Candidate for Checkpoint Blockade Immunotherapy
- (2015) Yanping Xiao et al. Cancer Discovery
- Adaptive Immune Resistance: How Cancer Protects from Immune Attack
- (2015) A. Ribas Cancer Discovery
- PDL1 Regulation by p53 via miR-34
- (2015) Maria Angelica Cortez et al. JNCI-Journal of the National Cancer Institute
- EBV-driven LMP1 and IFN-γ up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy
- (2015) Wenfeng Fang et al. Oncotarget
- Targeting hypoxia at the forefront of anticancer immune responses
- (2015) Muhammad Zaeem Noman et al. OncoImmunology
- Biochemical Signaling of PD-1 on T Cells and Its Functional Implications
- (2014) Vassiliki A. Boussiotis et al. CANCER JOURNAL
- Effects of MAPK and PI3K Pathways on PD-L1 Expression in Melanoma
- (2014) M. Atefi et al. CLINICAL CANCER RESEARCH
- Paclitaxel Induced B7-H1 Expression in Cancer Cells via the MAPK Pathway
- (2014) Wenrong Gong et al. JOURNAL OF CHEMOTHERAPY
- Blimp-1 represses CD8 T cell expression of PD-1 using a feed-forward transcriptional circuit during acute viral infection
- (2014) Peiyuan Lu et al. JOURNAL OF EXPERIMENTAL MEDICINE
- RGMb is a novel binding partner for PD-L2 and its engagement with PD-L2 promotes respiratory tolerance
- (2014) Yanping Xiao et al. JOURNAL OF EXPERIMENTAL MEDICINE
- MicroRNA-513 Regulates B7-H1 Translation and Is Involved in IFN- -Induced B7-H1 Expression in Cholangiocytes
- (2014) A.-Y. Gong et al. JOURNAL OF IMMUNOLOGY
- MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
- (2014) Thomas Powles et al. NATURE
- Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression
- (2014) Limo Chen et al. Nature Communications
- PD-L1 Expression in Triple-Negative Breast Cancer
- (2014) E. A. Mittendorf et al. Cancer Immunology Research
- A miR-570 binding site polymorphism in the B7-H1 gene is associated with the risk of gastric adenocarcinoma
- (2013) Weipeng Wang et al. HUMAN GENETICS
- PD-1 Increases PTEN Phosphatase Activity While Decreasing PTEN Protein Stability by Inhibiting Casein Kinase 2
- (2013) Nikolaos Patsoukis et al. MOLECULAR AND CELLULAR BIOLOGY
- Nivolumab plus Ipilimumab in Advanced Melanoma
- (2013) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- PTEN Loss Increases PD-L1 Protein Expression and Affects the Correlation between PD-L1 Expression and Clinical Parameters in Colorectal Cancer
- (2013) Minmin Song et al. PLoS One
- Immunotherapy for colorectal cancer
- (2013) Shigeo Koido WORLD JOURNAL OF GASTROENTEROLOGY
- Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors
- (2013) E. A. Akbay et al. Cancer Discovery
- Molecular Pathways: Next-Generation Immunotherapy--Inhibiting Programmed Death-Ligand 1 and Programmed Death-1
- (2012) D. S. Chen et al. CLINICAL CANCER RESEARCH
- The Activation of MAPK in Melanoma Cells Resistant to BRAF Inhibition Promotes PD-L1 Expression That Is Reversible by MEK and PI3K Inhibition
- (2012) X. Jiang et al. CLINICAL CANCER RESEARCH
- Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity
- (2012) Suzanne L Topalian et al. CURRENT OPINION IN IMMUNOLOGY
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Selective Effects of PD-1 on Akt and Ras Pathways Regulate Molecular Components of the Cell Cycle and Inhibit T Cell Proliferation
- (2012) N. Patsoukis et al. Science Signaling
- Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape
- (2012) J. M. Taube et al. Science Translational Medicine
- Cancer Immunotherapy Comes of Age
- (2011) Suzanne L. Topalian et al. JOURNAL OF CLINICAL ONCOLOGY
- Transcription factor T-bet represses expression of the inhibitory receptor PD-1 and sustains virus-specific CD8+ T cell responses during chronic infection
- (2011) Charlly Kao et al. NATURE IMMUNOLOGY
- New systemic treatment options for metastatic renal-cell carcinoma in the era of targeted therapies
- (2010) Thean Hsiang TAN et al. Asia-Pacific Journal of Clinical Oncology
- Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma
- (2010) M. R. Green et al. BLOOD
- B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance
- (2010) J.-J. Park et al. BLOOD
- Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma
- (2010) Ryosuke Hino et al. CANCER
- The Chromosomal Instability Pathway in Colon Cancer
- (2010) Maria S. Pino et al. GASTROENTEROLOGY
- Microsatellite Instability in Colorectal Cancer
- (2010) C. Richard Boland et al. GASTROENTEROLOGY
- Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
- (2010) Julie R. Brahmer et al. JOURNAL OF CLINICAL ONCOLOGY
- Transcriptional analysis of HIV-specific CD8+ T cells shows that PD-1 inhibits T cell function by upregulating BATF
- (2010) Michael Quigley et al. NATURE MEDICINE
- MicroRNAs: Target Recognition and Regulatory Functions
- (2009) David P. Bartel CELL
- PD-1 signaling in primary T cells
- (2009) James L. Riley IMMUNOLOGICAL REVIEWS
- PD-L1 regulates the development, maintenance, and function of induced regulatory T cells
- (2009) Loise M. Francisco et al. JOURNAL OF EXPERIMENTAL MEDICINE
- PD-1 and Its Ligands in Tolerance and Immunity
- (2008) Mary E. Keir et al. Annual Review of Immunology
- Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways
- (2008) Brian T. Fife et al. IMMUNOLOGICAL REVIEWS
- The AKT–mTOR axis regulates de novo differentiation of CD4+Foxp3+cells
- (2008) Sokol Haxhinasto et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection
- (2008) Shawn D Blackburn et al. NATURE IMMUNOLOGY
- Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1)
- (2008) M. Marzec et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started